Enlivex Therapeutics’ (ENLV) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a report issued on Wednesday morning,Benzinga reports. They currently have a $13.00 price target on the stock.

ENLV has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Enlivex Therapeutics in a research report on Friday, September 27th. EF Hutton Acquisition Co. I raised Enlivex Therapeutics to a “strong-buy” rating in a report on Tuesday, August 27th.

Enlivex Therapeutics Price Performance

NASDAQ:ENLV opened at $1.20 on Wednesday. Enlivex Therapeutics has a one year low of $0.81 and a one year high of $4.59. The company has a fifty day moving average price of $1.29 and a 200 day moving average price of $1.34. The stock has a market cap of $25.69 million, a P/E ratio of -1.22 and a beta of 1.01.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ENLV. XTX Topco Ltd acquired a new position in Enlivex Therapeutics in the second quarter worth about $35,000. Sigma Investment Counselors Inc. bought a new stake in shares of Enlivex Therapeutics in the 3rd quarter valued at approximately $50,000. Finally, Armistice Capital LLC acquired a new position in shares of Enlivex Therapeutics in the 2nd quarter worth approximately $2,415,000. 1.02% of the stock is owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.